251 related articles for article (PubMed ID: 25012726)
1. Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting.
He H; Yin JY; Xu YJ; Li X; Zhang Y; Liu ZG; Zhou F; Zhai M; Li Y; Li XP; Wang Y; Zhou HH; Liu ZQ
Clin Ther; 2014 Aug; 36(8):1242-1252.e2. PubMed ID: 25012726
[TBL] [Abstract][Full Text] [Related]
2. Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.
Perwitasari DA; Wessels JA; van der Straaten RJ; Baak-Pablo RF; Mustofa M; Hakimi M; Nortier JW; Gelderblom H; Guchelaar HJ
Jpn J Clin Oncol; 2011 Oct; 41(10):1168-76. PubMed ID: 21840870
[TBL] [Abstract][Full Text] [Related]
3. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.
Mattiuzzi GN; Cortes JE; Blamble DA; Bekele BN; Xiao L; Cabanillas M; Borthakur G; O'Brien S; Kantarjian H
Cancer; 2010 Dec; 116(24):5659-66. PubMed ID: 21218459
[TBL] [Abstract][Full Text] [Related]
4. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.
Babaoglu MO; Bayar B; Aynacioglu AS; Kerb R; Abali H; Celik I; Bozkurt A
Clin Pharmacol Ther; 2005 Dec; 78(6):619-26. PubMed ID: 16338277
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron.
Holdsworth MT; Raisch DW; Winter SS; Chavez CM
Support Care Cancer; 1998 Mar; 6(2):132-8. PubMed ID: 9540172
[TBL] [Abstract][Full Text] [Related]
6. Effect of the allelic variants of ABCB1, CYP2D6 and HTR3B on response of ramosetron to prevent chemotherapy-induced nausea and vomiting in Korean cancer patients.
Kang G; Kim KR; Shim HJ; Hwang JE; Bae WK; Chung IJ; Kim HN; Lee J; Choi K; Shin HY; Kim JK; Jeong SW; Cho SH
Asia Pac J Clin Oncol; 2017 Feb; 13(1):53-60. PubMed ID: 27488933
[TBL] [Abstract][Full Text] [Related]
7. Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia.
He H; Yin J; Li X; Zhang Y; Xu X; Zhai M; Chen J; Qian C; Zhou H; Liu Z
Eur J Clin Pharmacol; 2015 Mar; 71(3):293-302. PubMed ID: 25567217
[TBL] [Abstract][Full Text] [Related]
8. Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia.
Holdsworth MT; Raisch DW; Duncan MH; Chavez CM; Leasure MM
Ann Pharmacother; 1995 Jan; 29(1):16-21. PubMed ID: 7711340
[TBL] [Abstract][Full Text] [Related]
9. Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy.
Tsuji D; Matsumoto M; Kawasaki Y; Kim YL; Yamamoto K; Nakamichi H; Sahara Y; Makuta R; Yokoi M; Miyagi T; Itoh K
Cancer Chemother Pharmacol; 2021 Jan; 87(1):73-83. PubMed ID: 33099677
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 isoenzyme and ABCB1 gene polymorphisms associated with postoperative nausea and vomiting in women undergoing laparoscopic cholecystectomy: a randomized trial.
Ribeiro AHS; Braga ELC; Ferreira NAG; Olej B; Verçosa N; Antunes LDS; Cavalcanti IL
Braz J Anesthesiol; 2024; 74(3):744423. PubMed ID: 36841429
[TBL] [Abstract][Full Text] [Related]
11. A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting.
Singh KP; Dhruva AA; Flowers E; Kober KM; Miaskowski C
Crit Rev Oncol Hematol; 2018 Jan; 121():51-61. PubMed ID: 29279099
[TBL] [Abstract][Full Text] [Related]
12. Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting.
Choi EM; Lee MG; Lee SH; Choi KW; Choi SH
Anaesthesia; 2010 Oct; 65(10):996-1000. PubMed ID: 20707787
[TBL] [Abstract][Full Text] [Related]
13. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
14. [Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associated adverse events].
Kodama F; Mohri H; Motomura S; Fukawa H; Tanabe J; Koharasawa H; Kanamori H; Hashimoto Y; Harano H; Sakai R; Tomita N; Fujimaki K; Takemura S; Hattori M
Gan To Kagaku Ryoho; 2002 Feb; 29(2):273-9. PubMed ID: 11865634
[TBL] [Abstract][Full Text] [Related]
15. Improved anti-emetic efficacy of 5-HT3 receptor antagonists in cancer patients with genetic polymorphisms of ABCB1 (MDR1) drug transporter.
Zoto T; Kilickap S; Yasar U; Celik I; Bozkurt A; Babaoglu MO
Basic Clin Pharmacol Toxicol; 2015 Apr; 116(4):354-60. PubMed ID: 25286968
[TBL] [Abstract][Full Text] [Related]
16. Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine.
Badar T; Cortes J; Borthakur G; O'Brien S; Wierda W; Garcia-Manero G; Ferrajoli A; Kadia T; Poku R; Kantarjian H; Mattiuzzi G
Biomed Res Int; 2015; 2015():497597. PubMed ID: 25654108
[TBL] [Abstract][Full Text] [Related]
17. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis?
Candiotti KA; Birnbach DJ; Lubarsky DA; Nhuch F; Kamat A; Koch WH; Nikoloff M; Wu L; Andrews D
Anesthesiology; 2005 Mar; 102(3):543-9. PubMed ID: 15731591
[TBL] [Abstract][Full Text] [Related]
18. Control of nausea and vomiting with ondansetron in patients treated with intensive non-cisplatin chemotherapy for acute myeloid leukaemia.
Braken JB; Raemaekers JM; Koopmans PP; de Pauw BE
Eur J Cancer; 1993; 29A(4):515-8. PubMed ID: 8435201
[TBL] [Abstract][Full Text] [Related]
19. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of granisetron for preventing chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia treated with a combination of anthracycline and cytarabine].
Goto T; Tanimoto K; Ishibashi M; Okamura S
Gan To Kagaku Ryoho; 2012 Aug; 39(8):1227-32. PubMed ID: 22902447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
